AZN Stock Analysis: AstraZeneca | ST
Drug Manufacturers - General | ST, Sweden | Market Cap: 2.419.413m SEK | 12M Return: -0.9% | GB0009895292 | Charts, Fundamentals & Technical Analysis
Avg Turnover: 745M
EPS Trend: 96.9%
Qual. Beats: 1
Rev. Trend: 99.0%
Qual. Beats: 0
Warnings
Tailwinds
No distinct edge detected
Seasonality 11.7 years of data
How good or bad each month usually is (without trend). The score below shows how much you can trust it: 0 = pure chance, >40 gets interesting and >55 is strong.
AstraZeneca PLC is a UK-based biopharmaceutical company headquartered in Cambridge, founded in 1992 (as Zeneca Group PLC, renamed in 1999). It discovers, develops, manufactures, and commercializes prescription medicines across six main therapeutic areas: oncology, cardiovascular/renal/metabolism, respiratory and immunology, vaccines and immune therapies, and rare diseases. Its product portfolio spans flagship oncology drugs such as Tagrisso, Imfinzi, Lynparza, and Enhertu, as well as widely used primary-care medicines like Crestor, Nexium, and Farxiga. The company sells globally through distributors and local representative offices across the UK, the Americas, Europe, Asia, Africa, and Australasia, and has entered strategic collaborations with Tempus/Pathos (oncology AI), CSPC (oral drug discovery), and Nucs AI (radioconjugate response prediction).
Sector/Business Model Context: The biopharmaceutical industry is characterized by long R&D timelines, heavy reliance on patent-protected blockbuster drugs, and exposure to patent cliffs that erode revenue once exclusivity expires. AstraZenecas revenue model is driven by prescription medicines sold through physicians and healthcare providers, with oncology and rare disease biologics increasingly representing the companys higher-growth segments alongside its established primary-care franchises.
- Oncology sales surge led by Tagrisso, Imfinzi, and Enhertu
- China revenue decline pressures emerging markets segment growth
- US drug pricing reforms compress margins across oncology portfolio
| Net Income: 10.4b TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.08 > 0.02 and ΔFCF/TA 0.83 > 1.0 |
| NWC/Revenue: -5.90% < 20% (prev -8.14%; Δ 2.23% < -1%) |
| CFO/TA 0.12 > 3% & CFO 13.8b > Net Income 10.4b |
| Net Debt (30.3b) to EBITDA (20.6b): 1.47 < 3 |
| Current Ratio: 0.89 > 1.5 & < 3 |
| Outstanding Shares: last quarter (1.56b) vs 12m ago 0.06% < -2% |
| Gross Margin: 81.77% > 18% (prev 81.38%; Δ 0.39% > 0.5%) |
| Asset Turnover: 53.50% > 50% (prev 50.26%; Δ 3.24% > 0%) |
| Interest Coverage Ratio: 8.13 > 6 (EBIT TTM 14.2b / Interest Expense TTM 1.74b) |
| A: -0.03 (Total Current Assets 28.2b - Total Current Liabilities 31.8b) / Total Assets 117b |
| B: 0.11 (Retained Earnings 12.7b / Total Assets 117b) |
| C: 0.12 (EBIT TTM 14.2b / Avg Total Assets 115b) |
| D: 0.77 (Book Value of Equity 50.7b / Total Liabilities 66.0b) |
| Altman-Z'' = 1.79 = BBB |
| DSRI: 1.05 (Receivables 16.1b/14.2b, Revenue 61.3b/56.5b) |
| GMI: 1.00 (GM 81.38% / 81.77%) |
| AQI: 0.99 (AQ_t 0.62 / AQ_t-1 0.62) |
| SGI: 1.09 (Revenue 61.3b / 56.5b) |
| TATA: -0.03 (NI 10.4b - CFO 13.8b) / TA 117b) |
| Beneish M = -2.94 (Cap -4..+1) = A |
As of October 10, 2026, the stock is trading at SEK 1591.50 with a total of 430,714 shares traded. Over the past week, the price has changed by +1.11%, over one month by +4.77%, over three months by -6.36% and over the past year by -0.93%.
Current recommended Stop Loss: 1544.80 (which is 2.9% or 1.3 ATR below the current price).
AstraZeneca has no consensus analysts rating.
Market Cap USD = 242b (2419b SEK * 0.1 SEK.USD)
P/E Trailing = 24.9002
P/E Forward = 14.4718
P/S = 39.426
P/B = 5.1374
P/EG = 1.1715
Revenue TTM = 61.3b USD
EBIT TTM = 14.2b USD
EBITDA TTM = 20.6b USD
Long Term Debt = 23.7b USD (from longTermDebt, last quarter)
Short Term Debt = 6.29b USD (from shortTermDebt, last quarter)
Debt = 35.3b USD (from shortLongTermDebtTotal, last quarter) + Leases 2.75b
Net Debt = 30.3b USD (calculated: Debt 35.3b - CCE 5.01b)
Enterprise Value = 272b USD (242b + Debt 35.3b - CCE 5.01b)
Interest Coverage Ratio = 8.13 (Ebit TTM 14.2b / Interest Expense TTM 1.74b)
EV/FCF = 28.71x (Enterprise Value 272b / FCF TTM 9.48b)
FCF Yield = 3.48% (FCF TTM 9.48b / Enterprise Value 272b)
FCF Margin = 15.46% (FCF TTM 9.48b / Revenue TTM 61.3b)
Net Margin = 17.02% (Net Income TTM 10.4b / Revenue TTM 61.3b)
Gross Margin = 81.77% ((Revenue TTM 61.3b - Cost of Revenue TTM 11.2b) / Revenue TTM)
Gross Margin QoQ = 83.56% (prev 82.48%)
Tobins Q-Ratio = 2.33 (Enterprise Value 272b / Total Assets 117b)
Interest Expense / Debt = 4.95% (Interest Expense 1.74b / Debt 35.3b)
Taxrate = 16.95% (2.13b / 12.6b)
NOPAT = 11.8b (EBIT 14.2b * (1 - 16.95%))
Current Ratio = 0.89 (Total Current Assets 28.2b / Total Current Liabilities 31.8b)
Debt / Equity = 0.70 (Debt 35.3b / totalStockholderEquity, last quarter 50.7b)
Debt / EBITDA = 1.47 (Net Debt 30.3b / EBITDA 20.6b)
Debt / FCF = 3.19 (Net Debt 30.3b / FCF TTM 9.48b)
Total Stockholder Equity = 48.2b (last 4 quarters mean from totalStockholderEquity)
RoA = 9.11% (Net Income 10.4b / Total Assets 117b)
RoE = 21.68% (Net Income TTM 10.4b / Total Stockholder Equity 48.2b)
RoCE = 19.74% (EBIT 14.2b / Capital Employed (Equity 48.2b + L.T.Debt 23.7b))
RoIC = 13.34% (NOPAT 11.8b / Invested Capital 88.2b)
WACC = 5.16% (E(242b)/V(277b) * Re(5.31%) + D(35.3b)/V(277b) * Rd(4.95%) * (1-Tc(0.17)))
Discount Rate = 5.31% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: 26.90 | Cagr: 0.0%
[DCF] Terminal Value 77.97% ; FCFF base≈8.96b ; Y1≈10.3b ; Y5≈15.1b
[DCF] Fair Price = 127.2 (EV 228b - Net Debt 30.3b = Equity 197b / Shares 1.55b; r=8.35% [WACC [floored]]; 5y FCF grow 15.0% → 2.50% )
EPS Correlation: 96.93 | EPS CAGR: 12.94% | SUE: 1.53 | # QB: 1
Revenue Correlation: 98.99 | Revenue CAGR: 12.66% | SUE: -0.00 | # QB: 0
EPS current Quarter (2026-09-30): EPS=2.69 | Chg30d=+0.56% | Revisions=-25% | Analysts=2
EPS current Year (2026-12-31): EPS=10.45 | Chg30d=+0.64% | Revisions=+0% | GrowthEPS=+14.1% | GrowthRev=+7.5%
EPS next Year (2027-12-31): EPS=11.39 | Chg30d=+0.44% | Revisions=+0% | GrowthEPS=+9.0% | GrowthRev=+6.1%
[Analyst] Revisions Ratio: -12% (up=2, down=3)